481 related articles for article (PubMed ID: 30867304)
41. Sphingopeptides: dihydrosphingosine-based fusion inhibitors against wild-type and enfuvirtide-resistant HIV-1.
Ashkenazi A; Viard M; Unger L; Blumenthal R; Shai Y
FASEB J; 2012 Nov; 26(11):4628-36. PubMed ID: 22872679
[TBL] [Abstract][Full Text] [Related]
42. HIV-1 anchor inhibitors and membrane fusion inhibitors target distinct but overlapping steps in virus entry.
Eggink D; Bontjer I; de Taeye SW; Langedijk JPM; Berkhout B; Sanders RW
J Biol Chem; 2019 Apr; 294(15):5736-5746. PubMed ID: 30696772
[TBL] [Abstract][Full Text] [Related]
43. A novel antiretroviral class (fusion inhibitors) in the management of HIV infection. Present features and future perspectives of enfuvirtide (T-20).
Manfredi R; Sabbatani S
Curr Med Chem; 2006; 13(20):2369-84. PubMed ID: 16918361
[TBL] [Abstract][Full Text] [Related]
44. The M-T hook structure increases the potency of HIV-1 fusion inhibitor sifuvirtide and overcomes drug resistance.
Chong H; Yao X; Qiu Z; Sun J; Qiao Y; Zhang M; Wang M; Cui S; He Y
J Antimicrob Chemother; 2014 Oct; 69(10):2759-69. PubMed ID: 24908047
[TBL] [Abstract][Full Text] [Related]
45. Updating the use of synthetic peptides as inhibitors of HIV-1 entry.
Gómara MJ; Haro I
Curr Med Chem; 2014 Apr; 21(10):1188-200. PubMed ID: 23931277
[TBL] [Abstract][Full Text] [Related]
46. Enfuvirtide: the first HIV fusion inhibitor.
Lazzarin A
Expert Opin Pharmacother; 2005 Mar; 6(3):453-64. PubMed ID: 15794736
[TBL] [Abstract][Full Text] [Related]
47. Design of a highly potent HIV-1 fusion inhibitor targeting the gp41 pocket.
Chong H; Qiu Z; Su Y; Yang L; He Y
AIDS; 2015 Jan; 29(1):13-21. PubMed ID: 25562490
[TBL] [Abstract][Full Text] [Related]
48. Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41.
Xu W; Pu J; Su S; Hua C; Su X; Wang Q; Jiang S; Lu L
AIDS; 2019 Aug; 33(10):1545-1555. PubMed ID: 30932963
[TBL] [Abstract][Full Text] [Related]
49. Peptide and non-peptide HIV fusion inhibitors.
Jiang S; Zhao Q; Debnath AK
Curr Pharm Des; 2002; 8(8):563-80. PubMed ID: 11945159
[TBL] [Abstract][Full Text] [Related]
50. HIV-1 Entry and Membrane Fusion Inhibitors.
Xiao T; Cai Y; Chen B
Viruses; 2021 Apr; 13(5):. PubMed ID: 33922579
[TBL] [Abstract][Full Text] [Related]
51. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment.
Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
Antimicrob Agents Chemother; 2004 Sep; 48(9):3253-9. PubMed ID: 15328081
[TBL] [Abstract][Full Text] [Related]
52. Design of a Bispecific HIV Entry Inhibitor Targeting the Cell Receptor CD4 and Viral Fusion Protein Gp41.
Yan H; Wu T; Chen Y; Jin H; Li L; Zhu Y; Chong H; He Y
Front Cell Infect Microbiol; 2022; 12():916487. PubMed ID: 35711654
[TBL] [Abstract][Full Text] [Related]
53. Oregano Oil and Its Principal Component, Carvacrol, Inhibit HIV-1 Fusion into Target Cells.
Mediouni S; Jablonski JA; Tsuda S; Barsamian A; Kessing C; Richard A; Biswas A; Toledo F; Andrade VM; Even Y; Stevenson M; Tellinghuisen T; Choe H; Cameron M; Bannister TD; Valente ST
J Virol; 2020 Jul; 94(15):. PubMed ID: 32461309
[TBL] [Abstract][Full Text] [Related]
54. Peptide fusion inhibitors targeting the HIV-1 gp41: a patent review (2009 - 2014).
Zhang D; Li W; Jiang S
Expert Opin Ther Pat; 2015 Feb; 25(2):159-73. PubMed ID: 25428639
[TBL] [Abstract][Full Text] [Related]
55. Determinants of human immunodeficiency virus type 1 baseline susceptibility to the fusion inhibitors enfuvirtide and T-649 reside outside the peptide interaction site.
Heil ML; Decker JM; Sfakianos JN; Shaw GM; Hunter E; Derdeyn CA
J Virol; 2004 Jul; 78(14):7582-9. PubMed ID: 15220433
[TBL] [Abstract][Full Text] [Related]
56. Peptide-Based HIV Entry Inhibitors.
Pu J; Wang Q; Jiang S
Adv Exp Med Biol; 2022; 1366():15-26. PubMed ID: 35412132
[TBL] [Abstract][Full Text] [Related]
57. Enfuvirtide: a fusion inhibitor for the treatment of HIV infection.
Fung HB; Guo Y
Clin Ther; 2004 Mar; 26(3):352-78. PubMed ID: 15110129
[TBL] [Abstract][Full Text] [Related]
58. Inhibitors of viral entry.
Melby T; Westby M
Handb Exp Pharmacol; 2009; (189):177-202. PubMed ID: 19048201
[TBL] [Abstract][Full Text] [Related]
59. Structural Insights into the Mechanisms of Action of Short-Peptide HIV-1 Fusion Inhibitors Targeting the Gp41 Pocket.
Zhang X; Zhu Y; Hu H; Zhang S; Wang P; Chong H; He J; Wang X; He Y
Front Cell Infect Microbiol; 2018; 8():51. PubMed ID: 29535974
[TBL] [Abstract][Full Text] [Related]
60. Is there a future for antiviral fusion inhibitors?
Berkhout B; Eggink D; Sanders RW
Curr Opin Virol; 2012 Feb; 2(1):50-9. PubMed ID: 22440966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
